Background:To investigate the pharmacological effects of Fangshi Jiangtang decoction(FSJT)on type 2 diabetes mellitus(T2DM)model rats and explore its mechanism of action from the perspective of mitochondrial autophagy...Background:To investigate the pharmacological effects of Fangshi Jiangtang decoction(FSJT)on type 2 diabetes mellitus(T2DM)model rats and explore its mechanism of action from the perspective of mitochondrial autophagy.Methods:Sixty Sprague Dawley rats were randomly divided into six groups after one week of adaptive feeding:Control group,T2DM model group,metformin group(0.2 g/kg by gavage),and FSJT low,medium,and high dose groups(9.5,19,38 g/kg by gavage).Except for the Control group,the other five groups were given a high-fat diet.The treatment lasted for 8 weeks,and blood glucose levels were measured weekly.Eight weeks later,blood samples were collected from the rats,and serum was separated for the determination of HbA1c,oral glucose tolerance test,and homeostatic model assessment for insulin resistance index.The pancreas of the rats was collected,weighed,and fixed.The same part of the pancreas was used for hematoxylin-eosin.Kits were used to detect triglycerides,total cholesterol,interleukin-1β,interleukin-6,tumor necrosis factor-α,malondialdehyde,glutathione peroxidase,and superoxide dismutase in pancreatic tissue to assess the effects of FSJT on inflammation and oxidative stress in T2DM rats.Western blot analysis was performed to detect the expression of VDAC1,TOM20,COXⅣ,PINK1,Parkin,beclin1,light chain 3,and selective autophagy adaptor protein P62 to evaluate the effects of FSJT on mitochondrial autophagy in T2DM model rats.Results:Compared with the T2DM model group,FSJT intervention significantly reduced blood glucose,HbA1c,oral glucose tolerance test,and homeostatic model assessment for insulin resistance index in T2DM model rats,alleviated pancreatic tissue lesions,reduced levels of total cholesterol,triglycerides,interleukin-1β,interleukin-6,tumor necrosis factor-α,and malondialdehyde,increased glutathione peroxidase and superoxide dismutase activities,downregulated the expression of VDAC1,TOM20,COXⅣ,and P62 proteins,and upregulated the expression of PINK1,Parkin,Beclin1,and light chain 3 proteins.Conclusion:FSJT can improve insulin resistance in T2DM by promoting the activation of mitochondrial autophagy.展开更多
目的：观察益肾清利活血方联合大黄合剂灌肠治疗慢性肾脏病（CKD）2~3期患者的临床疗效。方法：采用随机对照的方法,将符合CKD2~3期的门诊或住院的70例患者分为治疗组（35例）和对照组（35例）。对照组给予基础治疗,治疗组加用益肾清利...目的：观察益肾清利活血方联合大黄合剂灌肠治疗慢性肾脏病（CKD）2~3期患者的临床疗效。方法：采用随机对照的方法,将符合CKD2~3期的门诊或住院的70例患者分为治疗组（35例）和对照组（35例）。对照组给予基础治疗,治疗组加用益肾清利活血方内服和大黄合剂灌肠治疗,连续观察6个月。观察指标包括：治疗前后的肾功能（BUN、Scr、eGFR）、24 h Upro、血常规、肝功能（ALB、ALT）、临床症状和生活质量（SF-36量表）,以及监测治疗期间不良反应。结果：最终完成观察研究65例,其中对照组32例,治疗组33例;与治疗前相比,治疗后两组患者的肾功能和24h Upro改善明显（P〈0.05或P〈0.01）,治疗组的改善效果优于对照组,但二者之间差异无统计学意义（P〉0.05）;与治疗前相比,治疗后两组患者的多个症状有明显改善（P〈0.05或P〈0.01）,治疗组与同期对照组相比,差异有统计学（P〈0.05）;与治疗前相比,两组患者的SF-36量表总体评分都有提高,但只有治疗组的一般情况（GH）、情感职能（RE）、社会功能（SF）、躯体疼痛（BF）和精力（VT）评分有统计学意义（P〈0.05或P〈0.01）,治疗组患者的GH、SF和VT评分与同期对照组的相比,差异有统计学意义（P〈0.05）;治疗中未发生严重不良反应。结论：益肾清利活血方联合大黄合剂灌肠可改善CKD2~3期患者的肾功能、24 h Upro、临床症状和生活质量,且具有良好的安全性,值得临床推广。展开更多
基金supported by Applied Basic Research Project of Jiaxing Science and Technology Bureau(2023AD11047)the Joint Project of Yunnan Provincial Science and Technology Department and Yunnan University of Chinese Medicine(202101AZ070001-064).
文摘Background:To investigate the pharmacological effects of Fangshi Jiangtang decoction(FSJT)on type 2 diabetes mellitus(T2DM)model rats and explore its mechanism of action from the perspective of mitochondrial autophagy.Methods:Sixty Sprague Dawley rats were randomly divided into six groups after one week of adaptive feeding:Control group,T2DM model group,metformin group(0.2 g/kg by gavage),and FSJT low,medium,and high dose groups(9.5,19,38 g/kg by gavage).Except for the Control group,the other five groups were given a high-fat diet.The treatment lasted for 8 weeks,and blood glucose levels were measured weekly.Eight weeks later,blood samples were collected from the rats,and serum was separated for the determination of HbA1c,oral glucose tolerance test,and homeostatic model assessment for insulin resistance index.The pancreas of the rats was collected,weighed,and fixed.The same part of the pancreas was used for hematoxylin-eosin.Kits were used to detect triglycerides,total cholesterol,interleukin-1β,interleukin-6,tumor necrosis factor-α,malondialdehyde,glutathione peroxidase,and superoxide dismutase in pancreatic tissue to assess the effects of FSJT on inflammation and oxidative stress in T2DM rats.Western blot analysis was performed to detect the expression of VDAC1,TOM20,COXⅣ,PINK1,Parkin,beclin1,light chain 3,and selective autophagy adaptor protein P62 to evaluate the effects of FSJT on mitochondrial autophagy in T2DM model rats.Results:Compared with the T2DM model group,FSJT intervention significantly reduced blood glucose,HbA1c,oral glucose tolerance test,and homeostatic model assessment for insulin resistance index in T2DM model rats,alleviated pancreatic tissue lesions,reduced levels of total cholesterol,triglycerides,interleukin-1β,interleukin-6,tumor necrosis factor-α,and malondialdehyde,increased glutathione peroxidase and superoxide dismutase activities,downregulated the expression of VDAC1,TOM20,COXⅣ,and P62 proteins,and upregulated the expression of PINK1,Parkin,Beclin1,and light chain 3 proteins.Conclusion:FSJT can improve insulin resistance in T2DM by promoting the activation of mitochondrial autophagy.
文摘目的：观察益肾清利活血方联合大黄合剂灌肠治疗慢性肾脏病（CKD）2~3期患者的临床疗效。方法：采用随机对照的方法,将符合CKD2~3期的门诊或住院的70例患者分为治疗组（35例）和对照组（35例）。对照组给予基础治疗,治疗组加用益肾清利活血方内服和大黄合剂灌肠治疗,连续观察6个月。观察指标包括：治疗前后的肾功能（BUN、Scr、eGFR）、24 h Upro、血常规、肝功能（ALB、ALT）、临床症状和生活质量（SF-36量表）,以及监测治疗期间不良反应。结果：最终完成观察研究65例,其中对照组32例,治疗组33例;与治疗前相比,治疗后两组患者的肾功能和24h Upro改善明显（P〈0.05或P〈0.01）,治疗组的改善效果优于对照组,但二者之间差异无统计学意义（P〉0.05）;与治疗前相比,治疗后两组患者的多个症状有明显改善（P〈0.05或P〈0.01）,治疗组与同期对照组相比,差异有统计学（P〈0.05）;与治疗前相比,两组患者的SF-36量表总体评分都有提高,但只有治疗组的一般情况（GH）、情感职能（RE）、社会功能（SF）、躯体疼痛（BF）和精力（VT）评分有统计学意义（P〈0.05或P〈0.01）,治疗组患者的GH、SF和VT评分与同期对照组的相比,差异有统计学意义（P〈0.05）;治疗中未发生严重不良反应。结论：益肾清利活血方联合大黄合剂灌肠可改善CKD2~3期患者的肾功能、24 h Upro、临床症状和生活质量,且具有良好的安全性,值得临床推广。
